EUVIMEDEUVIMED entdecken
Open Access

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Teri J Mauch iD, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Christoph Gasteyger, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds und 2 weitere

Journal of Comparative Effectiveness Research · 2023

DOI: 10.57264/cer-2023-0036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023. Verfasst von Teri J Mauch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology, University of Nebraska Medical Center & Omaha Children's Hospital, Omaha, NE 68114, USA. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients' treatment preferences and the impact of both treatments on patient and caregiver quality of life. Materials & methods: Two surveys were conducted (one for adult patients with aHUS and one for caregivers of pediatric patients with aHUS) to quantitatively assess treatment preference and the patient- and caregiver-reported impact of ravulizumab and eculizumab on quality of life. Patients were required to have a diagnosis of aHUS, to be currently receiving treatment with ravulizumab and to have received prior treatment with eculizumab. Participants were recruited via various sources: the Alexion OneSource™ patient support program, the Rare Patient Voice recruitment agency, the aHUS Foundation and directly via a clinician involved in the study.

Results

In total, 50 adult patients (mean age: 46.5 years) and 16 caregivers of pediatric patients (mean age: 10.1 years) completed the surveys. Most adult patients (94.0%) and all caregivers reported an overall preference for ravulizumab over eculizumab; infusion frequency was one of the main factors for patients when selecting their preferred treatment. Fewer patients reported disruption to daily life and the ability to go to work/school due to ravulizumab infusion frequency (4.0% and 5.7%, respectively) than eculizumab infusion frequency (72.0% and 60.0%), with similar results for caregivers.

Conclusion

Adult patients and caregivers of pediatric patients indicated an overall preference for ravulizumab than eculizumab for the treatment of aHUS, driven primarily by infusion frequency. This study contributes to the emerging real-world evidence on the treatment impact and preference in patients with aHUS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atypical Hemolytic Uremic SyndromeAdultHumansChildMiddle AgedQuality of LifeAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Stichwörter der Autor:innen

aHUSatypical hemolytic uremic syndromecaregiver preferenceeculizumabpatient preferencepatient-reported outcomesquality of liferavulizumabtreatment preference

Substanzen

ravulizumabeculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Division of Pediatric Nephrology, University of Nebraska Medical Center & Omaha Children's Hospital, Omaha, NE 68114, USA.
  • Clinical Outcomes Assessments & Quantitative Sciences, Clinical Outcomes Solutions, LLC, Chicago, IL 60604, USA.
  • Division of Hematology, Wexner Medical Center, Ohio State University, Columbus, OH 43203, USA.
  • Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
  • Alexion, AstraZeneca Rare Disease, Boston, MA 02210, USA.

ORCID-Profile: Teri J Mauch

Zitieren

APA

Mauch, T. J., Chladek, M. R., Cataland, S., Chaturvedi, S., Dixon, B. P., Garlo, K., Gasteyger, C., Java, A., Leguizamo, J., Lloyd-Price, L., Pham, T. P., Symonds, T., Tomazos, I., & Wang, Y. (2023). Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0036

Vancouver

Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, et al. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. Journal of Comparative Effectiveness Research. 2023. doi:10.57264/cer-2023-0036

BibTeX
@article{Mauch2023,
  author = {Mauch, Teri J and Chladek, Michael R and Cataland, Spero and Chaturvedi, Shruti and Dixon, Bradley P and Garlo, Katherine and Gasteyger, Christoph and Java, Anuja and Leguizamo, Jorge and Lloyd-Price, Lucy and Pham, Tan P and Symonds, Tara and Tomazos, Ioannis and Wang, Yan},
  title = {Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  doi = {10.57264/cer-2023-0036}
}
Kostenlos starten →